Advertisement
UK markets close in 5 minutes
  • FTSE 100

    8,437.76
    +56.41 (+0.67%)
     
  • FTSE 250

    20,637.54
    +106.24 (+0.52%)
     
  • AIM

    790.19
    +6.49 (+0.83%)
     
  • GBP/EUR

    1.1618
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2513
    -0.0010 (-0.08%)
     
  • Bitcoin GBP

    48,892.30
    -506.80 (-1.03%)
     
  • CMC Crypto 200

    1,262.15
    -95.86 (-7.05%)
     
  • S&P 500

    5,216.25
    +2.17 (+0.04%)
     
  • DOW

    39,448.92
    +61.16 (+0.16%)
     
  • CRUDE OIL

    79.12
    -0.14 (-0.18%)
     
  • GOLD FUTURES

    2,368.50
    +28.20 (+1.20%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,756.66
    +70.06 (+0.37%)
     
  • CAC 40

    8,213.39
    +25.74 (+0.31%)
     

Molina Healthcare's (NYSE:MOH) five-year total shareholder returns outpace the underlying earnings growth

Molina Healthcare, Inc. (NYSE:MOH) shareholders might be concerned after seeing the share price drop 13% in the last month. But over five years returns have been remarkably great. To be precise, the stock price is 331% higher than it was five years ago, a wonderful performance by any measure. Arguably, the recent fall is to be expected after such a strong rise. Of course what matters most is whether the business can improve itself sustainably, thus justifying a higher price.

While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.

View our latest analysis for Molina Healthcare

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

ADVERTISEMENT

During five years of share price growth, Molina Healthcare achieved compound earnings per share (EPS) growth of 44% per year. The EPS growth is more impressive than the yearly share price gain of 34% over the same period. So it seems the market isn't so enthusiastic about the stock these days.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

Dive deeper into Molina Healthcare's key metrics by checking this interactive graph of Molina Healthcare's earnings, revenue and cash flow.

A Different Perspective

It's nice to see that Molina Healthcare shareholders have received a total shareholder return of 11% over the last year. However, that falls short of the 34% TSR per annum it has made for shareholders, each year, over five years. Potential buyers might understandably feel they've missed the opportunity, but it's always possible business is still firing on all cylinders. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Molina Healthcare is showing 2 warning signs in our investment analysis , you should know about...

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.